BLB(SZ:002286)2022-04-28 16:00Financial Performance - The company reported a significant profit increase driven by the rapid launch of new projects in the biological sector, particularly with erythritol and allulose, aligning with changing consumer trends[144]. - The company achieved a revenue of 2.765 billion yuan in 2021, representing a year-on-year growth of 34.58%[96]. - The net profit attributable to shareholders reached 202 million yuan, a significant increase of 304.28% compared to the previous year[96]. - The company's operating revenue for 2021 was ¥2,764,976,972.69, representing a 34.58% increase compared to ¥2,054,578,268.02 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥201,579,400.15, a significant increase of 304.28% from ¥49,861,881.27 in 2020[21]. - The net profit after deducting non-recurring gains and losses was ¥164,369,745.11, reflecting a 353.28% increase compared to ¥36,262,261.21 in 2020[21]. - The company reported a quarterly operating revenue of ¥815,251,756.04 in Q3 2021, the highest among the four quarters[25]. - The company achieved a net profit of ¥184,030,967.09 for the year 2021, with a total distributable profit of ¥510,103,521.31 after accounting for legal reserves and previous undistributed profits[197]. Dividend Distribution - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares to all shareholders, based on a total of 371,911,900 shares[5]. - The cash dividend distribution plan for 2021 is set at ¥0.60 per 10 shares (including tax), totaling ¥22,314,714.00, which represents 100% of the profit distribution[197]. - The company has not proposed any cash dividend distribution plan for the current reporting period despite having positive distributable profits[197]. Research and Development - The company is investing in research and development of new products and technologies to enhance its competitive edge in the market[12]. - The company achieved a research and development investment of ¥100,613,062.55 in 2021, representing a 58.05% increase from ¥63,659,830.52 in 2020[118]. - R&D investment accounted for 3.64% of total revenue in 2021, up from 3.10% in the previous year, indicating a focus on innovation[118]. - The number of R&D personnel increased to 153 in 2021, a rise of 4.79% from 146 in 2020[117]. - The company completed key technology research for the green preparation of resistant dextrin, aiming to enhance production efficiency and reduce costs[114]. - The company is developing new products such as lactulose to expand its existing product line[114]. - The company has established key technologies for the production of high-end modified starches, aimed at increasing market share in international markets[116]. - The company is conducting research on the high-value utilization of lactose, aiming to enhance product variety and market competitiveness[116]. Market Position and Strategy - The company is focused on expanding its product offerings in functional foods, which are designed to enhance health without treating diseases[12]. - The company has outlined its future development outlook, which includes strategies for market expansion and potential mergers and acquisitions[5]. - The company operates in the functional sugar industry, focusing on enzyme engineering and fermentation technology, with a diverse product range including functional sugars and dietary fibers[30]. - The company has a strong market presence with a diversified product structure and a robust marketing network, achieving significant market share in various segments of functional sugars[75]. - The company is positioned as the only full-category functional sugar manufacturer in the domestic market, leveraging its core technology and full industry chain advantages[81]. - The company is actively pursuing capacity cooperation and expanding its import and OEM business to achieve high-quality growth during the reporting period[97]. - The company aims to enhance its market presence by exploring new applications and developing new downstream industry clients to reduce dependency on large customers[147]. Governance and Management - The company emphasizes the importance of accurate and complete financial reporting, with key executives confirming the integrity of the annual report[4]. - The report includes a comprehensive overview of the company's governance and social responsibility initiatives, indicating a commitment to ethical practices[7]. - The company has established a comprehensive human resources management system, ensuring independent personnel management[159]. - The company has a clear and independent organizational structure, with strict adherence to corporate governance[160]. - The company has undergone significant changes in its supervisory board, with new members being elected to enhance governance[166]. - The company is committed to maintaining a robust governance structure through regular board elections and appointments[166]. Risk Management - The management discussion highlights potential risks the company may face in future operations, urging investors to be aware of investment risks[5]. - The company emphasizes risk management strategies to mitigate raw material price fluctuations, including futures hedging and improving production processes[146]. - The company has established a hedging management system to control risks associated with futures trading and ensure compliance with relevant regulations[141]. - The report highlighted a focus on risk management strategies to mitigate potential losses from market fluctuations[133]. Product Development and Innovation - The company has developed and industrialized new products including allulose, precision prebiotics, and low-viscosity maltotetraose, further enhancing its product portfolio[76]. - The company is positioned to leverage its first-mover advantage in the health industry, focusing on a core health industry system based on biological ingredients[141]. - The company has completed the industrialization of resistant starch production, which is expected to meet customer demands and enhance market competitiveness[116]. - The company is in the process of developing a new strain of erythritol to meet strong market demand, which will drive rapid growth[116]. Financial Management - The company operates independent financial management, with a dedicated finance department and accounting system[160]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 10.86 million CNY[181]. - The highest remuneration was received by the General Manager, who earned 1.71 million CNY[182]. - The company adheres to a remuneration policy that links income levels to company performance and individual performance assessments[181]. - The company has implemented a strategic procurement decision-making process to maximize profits while managing raw material costs[96].